Latest research on Ezetimibe

Ezetimibe is an anti-hyperlipidemic medication which is used to lower cholesterol levels. Specifically, it appears to bind to a critical mediator of cholesterol absorption, the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract epithelial cells as well as in hepatocytes.

Latest findings

The statin effects on EPC activity appear to be independent of the impact on LDL-C reduction, as shown by the comparison of Simvastatin with Ezetimibe administration [69], suggesting that the beneficial effect of lipid lowering drugs on the endothelium health status may be enhanced by EPC stimulation. [source, 2016]
The LDL-lowering effects of evacetrapib were being evaluated in the multicenter “Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia” (ACCENTUATE) study (ClinicalTrials.gov Identifier: NCT02227784) [www.clinicaltrials.gov/ct2/show/NCT02227784]. [source, 2016]
Mortality caused by atherosclerotic coronary artery disease is expected to remain high even with statins and Ezetimibe being used as a standard of care and a new antibody therapy against the proprotein convertase subtilisin/kexin 9 reaching the market (1). [source, 2016]
They also tackle the perceived risks of dropping low-density lipoprotein cholesterol (LDL-C) too low, using medication on top of statins, namely Ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies; the latter showing no difference in adverse events with patients achieving on-treatment LDL above or below 25 mg/ml (0.65 mmol/l), a level that would have been unachievable a few years ago. [source, 2016]
The combination of Simvastatin (40 mg) and Ezetimibe (10 mg) was compared with Simvastatin (40 mg) and placebo. [source, 2016]
Probably the best answer to this question regarding the role of statins in secondary prevention is the fact that all available (Ezetimibe, Fenofibrate) and currently investigated (e.g. PCSK9 and CETP inhibitors) drugs are mainly considered for use ‘on top of’ statins. [source, 2016]
To define pharmacotherapy use, participants were asked to list all current medications, allowing determination of Acetylsalicylic acid, statin, Ezetimibe, fibrate, and RAS inhibitor use; history of side-effects, drug intolerance, and duration of therapy were not ascertained. [source, 2016]
SHARP was a randomized placebo-controlled trial investigating the effects of lowering low-density lipoprotein cholesterol levels for an average of 5 years with Simvastatin, 20 mg, plus Ezetimibe, 10 mg, daily on major vascular and kidney disease outcomes. [source, 2016]
For the purpose of the current analyses, baseline information refers to information that was recorded at or shortly before a participant’s random assignment to Simvastatin plus Ezetimibe versus placebo. [source, 2016]
All analyses were adjusted for age, sex, ethnicity (black vs white/other), and allocation to Simvastatin plus Ezetimibe (vs placebo) and stratified by country of recruitment. [source, 2016]